Y-mAbs Therapeutics, Inc. Forecast, price target & analysts
Y-mAbs Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation
Y-mAbs Therapeutics, Inc. Classifications & Recommendation:
Y-mAbs Therapeutics, Inc. Price Target
| Target Price | $15.42 |
| Price | $4.23 |
| Potential |
264.46%
register free of charge
|
| Number of Estimates | 12 |
|
12 Analysts have issued a price target Y-mAbs Therapeutics, Inc. 2026 .
The average Y-mAbs Therapeutics, Inc. target price is $15.42.
This is
264.46%
register free of charge
$26.00
514.66%
register free of charge
$3.00
29.08%
register free of charge
|
|
| A rating was issued by 12 analysts: 10 Analysts recommend Y-mAbs Therapeutics, Inc. to buy, 0 to hold and 2 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Y-mAbs Therapeutics, Inc. stock has an average upside potential 2026 of
264.46%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 87.69 | 83.18 |
| 3.38% | 5.14% | |
| EBITDA Margin | -33.23% | -47.92% |
| 37.76% | 44.20% | |
| Net Margin | -34.57% | -53.64% |
| 32.26% | 55.15% |
12 Analysts have issued a sales forecast Y-mAbs Therapeutics, Inc. 2025 . The average Y-mAbs Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Y-mAbs Therapeutics, Inc. EBITDA forecast 2025. The average Y-mAbs Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
10 Y-mAbs Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average Y-mAbs Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.67 | -0.99 |
| 36.73% | 47.76% | |
| P/E | negative | |
| EV/Sales | 1.59 |
10 Analysts have issued a Y-mAbs Therapeutics, Inc. forecast for earnings per share. The average Y-mAbs Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Y-mAbs Therapeutics, Inc....
Current Y-mAbs Therapeutics, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | May 19 2025 |
| Oppenheimer |
Locked
➜
Locked
|
Locked | May 14 2025 |
| Truist Securities |
Locked
➜
Locked
|
Locked | May 14 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 21 2025 |
| B of A Securities |
Locked
➜
Locked
|
Locked | Mar 05 2025 |
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Mar 05 2025 |
| Truist Securities |
Locked
➜
Locked
|
Locked | Mar 05 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
May 19 2025 |
|
Locked
Oppenheimer:
Locked
➜
Locked
|
May 14 2025 |
|
Locked
Truist Securities:
Locked
➜
Locked
|
May 14 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 21 2025 |
|
Locked
B of A Securities:
Locked
➜
Locked
|
Mar 05 2025 |
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Mar 05 2025 |
|
Locked
Truist Securities:
Locked
➜
Locked
|
Mar 05 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
